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Summary: We describe a high-perfonnance single-run liquid Chromatographie method for the Separation of
protein-bound and "free" (loosely bound) bilifubin in human serum samples. The procedure is based on both
the size-exclusion and the adsorptive properties of the column packing material, LiChrosorb Diol. The elution
of all sample constituents is accomplished by means of an aqueous mobile phase containing a phosphate-
buffered solution of human serum albumin or adult serum, supplemented by a small amount of bilirubin.
The efficacy of the developed method is exemplified by assaying the bilirubin binding to human adult and
infant sera.
Introduction Materials and Methods
In 1979 Lu et al. (1) reported a liquid chromato- Reagents
graphic (HPLC) method for the fractionation of pro- unhaemolysed adult serum (AS; 2.9 mg/1 of total bilirubin),
tein-bound and free bilirubin. In this method, a sam- two different samples of infant serum (ISi and IS2; 129 and 102
ple of serum, applied onto the HPLC column, packed ^δ/1 °/ tootal b irubinrespectively) human serum albumin
• t_ r, ^,i_ t ,̂τ^ <ΛΛ · i . j -Λ u t * (No. A 1887, Sigma, St. Louis, MO, USA), bilirubin p.a.with SynChropak GPC 100, is eluted with phosphate ^erck> Darmstadt, FRG), dithioerythritol 99% (Aldrich-Eu-
buffer (0.01 mol/1, pH 7.4), and the effluent is moni- rope, Beerse, Belgium), KH2PO4 p. a., and Na2HPO4 χ 12 H2O
t red at 453 nm. Protein-bound pigment passes unre- P·a·
tained through the column, while free bilirubin, re-
tained on the column, is released by subsequerit re-
peated injections of a 0.1 mmol/1 solution of bovine Working solutions
5erum albumin in the eluent. Bilirubin, 20 mg, was dissolved in 3 ml of NaOH solution (0.1
mol/1) in a 10-ml voltimetric flask, followed by the addition of
In the present work, bilirubin binding in human serum 30 mg of dithioerythritol. The solution was adjusted to 10 ml
was studied by HPLC, using a solution of protein(s) ™* Phosphate buffer (0.01 mol/1, pH 7.4) A blank working
·ι· i · t- u-i t. solution without bilirubin was prepared by the same procedure.
plus a small amount of bilirubin s the mobile phase Both working solutions were kept frozen until use. All manip-
to release the pigment fraction that is otherwise trap- ulations involving bilirubin were performed in dim light.
ped by the colunm filling material.
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Mobile phase
A phosphate-buffered (0.067 mol/1, pH 7.4) solution of I: hu-
man serum albumin (80 mg/1) or II: adult serura (2 ml/l), to
which a small volume of the bilirubin working solution had
been added (1000:0.05, v/v), was filtered through a Waters
Assoc. ultrafilter membrane (porosity 0.45 μπι) and immediately
used s eluent. Redistilled water was used for the preparation
of the phosphate buffer.
Apparatus
A Waters Assoc. pump (Model 6000 A solvent delivery System),
a Rheodyne injection valve (Model 7120) equipped with a 10 μί
loop, and a Waters Assoc. photometric detector (Model 440)
operated with a 436 nm filter were used for all the experiments.
Separations were carried out at room temperature in a stainless
steel column, 15 cm χ 4.7 mm (i. d.), packed with LiChrosorb
Diol, mean particle size 5 μηι (Merck, Darmstadt, FRG). The
mobile phase was pumped at a flow-rate of l ml/min. The
Container bottle s well s the teflon tubings were wrapped in
aluminum foil to protect the eluent from light.
Samples
Samples for analysis were prepared freshly by appropriately
mixing the two working Solutions with serum. In the set assayed,
with the sample? coded a—m, the dilution factor of serum was
0.6. A 10-μΙ sample thus contained 6 μΐ of serum and 4 μΐ of a
diluent. Dilutions were performed to obtain the following con-
centrations of exogenous bilirubin: 0, 0.0625, 0.125, 0.1875,
0.25, 0.3125, 0.375, 0.5, 0.625, 0.75, l, 1.5, and 2 g/l.
Results
The HPLC elution profiles of the assayed set of adult
serum samples obtained with eluent I are shown in
figure 1. The chromatogram of the diluted serum
sample containing no exogenous bilirubin (fig. l, a)
shows two peaks. The HPLC analysis of samples
containing exogenous bilirubin showed (see fig. l,
b —m) that small amounts of added pigment were
preferentially bound to the protein with longer reten-
tion time, while at higher concentrations of exogenous
bilirubin protein with shorter retention time became
pronouncedly stained and, moreover, a plateau at the
higher retention time kept expanding.
Figures 2 and 3 show the results obtained by assaying
the bilirubin binding to two different samples of infant
serum (ISj, IS2) using eluent II. (The sample IS2 with
a lower total bilirubin level came from the group of
infants whose hyperbilirubinaemia was less physio-
logical than that in another group.) The chromato-
gram of the diluted ISi sample containing no exoge-
nous bilirubin (see fig. 2, a) showed only one peak.
The ability of the other, the less retained protein to
bind bilirubin was confirmed at relatively high levels
of the exogenous pigment (cf. fig. 2, i-m). Likewise,
the results of the HPLC analysis of sample IS2 (see
fig. 3) imply that endogenous bilirubin s well s all




Fig. 1. HPLC elution profiles of the assayed set of adult serum
(AS) samples a—m.
The actual level pf total bilirubin in samples a—m was
1.74, 26.74, 51.74, 76.74, 101.74,126.74,151.74, 201.74,
251.74, 301.74, 401.74, 601.74, and 801.74 mg/1, respec-
tively. (During the analysis of the samples coded a—k
the attenuation of the detector was set to l, while the
recording of the samples coded l and m, shown in the
upper right corner of the panel, was obtained at
attenuation 2.)
equally between the two serum proteins. Unlike adult
serum, the HPLC analysis of both infant serum sam-
ples revealed the presence of a plateau even in the
absence of the exogenous pigment ($ee figs. 2, a, and
35a). It should be noted that-'the1 actual level of total
bilirubin in the samples eoded c and d of the set of
bilirubin containing AS samples (51.14 and 76.74
mg/1) is virtually the same s the level in the sample
coded a of the ISi (77.4 mg/1) or IS2 (61.2 mg/1)
samples.
The within-day repeatability of the developed Chro-
matographie method was determined from the area
under the HPLC record for samples containing 200
mg/1 of exogenous bilirubin (samples coded h). Coef-
ficients of Variation from quadruplicate determina-
tions were: 2.2% and 1.3% for the AS sample using
eluents I and II, respectively; and 2.2% and 3.6% for
ISt and IS2, respectively, using eluent II.
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Fig. 2. HPLC elution profiles of the assayed set of infant serum
(ISj) samples a—m.
The actual level of total bilirubin in samples a—m was
77.4, 102.4, 127.4, 152.4, 177.4, 202.4, 227.4, 277.4,








Fig. 3. HPLC elution profiles of the assayed set of infant serum
(IS2) samples a—m.
The actual level of total bilirubin in samples a—m was
61.2, 86.2,111.2,136.2,161.2,186.2, 211.2, 261.2, 311.2,
361.2, 461.2, 661.2, and 861.2 mg/1, respectively.
Discussion
This study was initiated by investigating the ability
of phosphate-buffered (0.067 mol/1, pH 7.4) Solutions
of human serum albumin (40—400 mg/1 of protein)
to elute bilirubin from the column. At the highest
protein concentration (400 mg/1) in the eluent, the
bilirubin of adult serum samples was totally eluted in
a single peak, whereas at the lowest albumin concen-
tration (40 mg/1), the free (loosely bound) bilirubin
fraction was trapped by the column filling material.
According to Lu et al. (1) this 'fraction of bilirubin
can be fully recovered from LiChrosorb Diol simply
by means of several injections of e. g. the eluent with
the highest albumin concentration.
In the next Step, the effect of bilirubin added to the
eluent was studied on the HPLC elution patterns. On
the basis of these experiments it can be concluded
that the addition of bilirubin to the mobile phase
resulted in an improved symmetry of the peak(s) äs
well äs a suppression of the drift of the baseline
between HPLC runs. By using the phosphate buffered
human serum albumin solution of 80 mg/1 mixed with
the bilirubin working solution in the volume ratio of
1000:0.05 (eluent I), we were able to resolve, in one
single run, each bilirubin fraction in samples of human
serum.
Comparison of the results given in figure l with those
reported by Cooke & Roberts (2) shows an excellent
agreement. These authors studied the distribution of
bilirubin in serum proteins separated on Sephadex -
00, by monitoring the UV/VIS light abso tion of
the effluent. They passed diluted adult sera containing
exogenous bilirubin through the column eluted with
phosphate buffer (0.067 mol/1, pH 7.4), and obtained
two peaks of protein-bound bilirubin. The leading
peak was ß-lipoprotein-bilirubin associate, and the
other peak was the albumin^bilirubin complex. Re-
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peated applications of each individual fraction sepa-
rately to the columns of Sephadex G-100 showed
different abilities of the two proteins to bind bilirubin.
When the stained ß-lipoprotein was run through the
column a pigment trail remained, but this behaviour
was not shown by the albumin containing fraction. It
was found that the pigment remaining inside the col-
umn could be eluted with additional serum. These
experiments suggest that Sephadex G-100 competes
for bilirubin by an active adsorption effect and that
the complex of the pigment with lipoprotein is less
stable than that with albumin.
Phenomena similar to those reported by Cooke &
Roberts (2) could be assumed to be present in our
experimental setting, since attraction between Li-
Chrosorb Diol and protein(s)-bilirubin complexes can
be expected (see fig. 1). Therefore, under our experi-
mental conditions (eluent I), the distribution of exo-
genous bilirubin between the two proteins, äs well äs
the amount of the loosely bound (dissociable) pigment
fraction can ,be determined during one single Chro-
matographie run. The relatively constant height of
the plateau observed on the HPLC elution profile of
the samples coded h—m (cf. fig. l, h—m) is most
probably maintained by the reserve albumin binding
capacity of the eluent L By using this mobile phase
the fraction of bilirubin retarded by LiChrosorb Diol
is released, due to the affinity of the pigment for the
unoccupied binding sites of albumin in the eluent.
Replacement of human serum albumin in the mobile
phase by adult serum (2 ml/l) (i. e. the use of eluent
II) did not markedly influence the character of the
HPLC elution profile of the assayed adult serum
samples; chromatograms showed a similar superpo-
sition of peaks and plateaus. The observed slightly
diminished resolution of individual serum proteins
stained with bilirubin (not shown) with eluent II can
be accounted for by the blockade of LiChrosorb Diol
pores with constituents of the mobile phase. However,
the use of such a multicomponent mobile phase
caused a significant suppression of the liberation (dis-
sociation) of the pigment from the protein(s)-bilirubin
complexes due to its adsorption to LiChrosorb Diol.
That is why eluent II was preferred for assaying the
infant serum samples (ISt, IS2).
To clarify the origin of the peaks and plateau on the
chromatograms of IS,, IS2 and AS, the phosphate-
buffered (0.067 mol/1, pH 7.4) Solutions of human
serum albumin (40 g/l), diluted (6:4, v/v) with the
giveri set of the exogenous bilirubin diluent (see Ma-
terials and Methods; "Samples"), were run through
the HPLC assay using eluents I and II. The elucida-
tion of the HPLC behaviour of bilirubin-stained ß-
lipoprotein samples is limited, since the pure protein
is not commercially available. It woüld be possible to
use the commercially available fraction of low density
lipoproteins, which contains the ß-lipoprotein in ques-
tion, but this has not been tried in the present study.
In chromatograms of human serum albumin samples
stained with a sufficient amount of bilirubin (samples
d — m using eluent II, c—m using eluent I), the peak
and plateau are superimposed (not shown). The Chro-
matographie peak-plateau pattern of the bilirubin
stained human serum albumin samples (d—m) closely
resembled the pattern of ISi samples (a—h). Therefore
the other peak, which precedes the albumin and is
seen in e. g. HPLC separations of heavily stained ISi
samples (see fig. 2, i—m), might originate from the
stained ß-lipoprotein. Such a Statement can so far be
supported only indirectly by taking into account the
size-exclusion properties of the used LiChrosorbDiol
and the substantially higher molecular weight ß^li*
poprotein äs compared with that of albumin.
Assuming that bilirubin bound to ß-lipoprötein and
to albumin, and bilirubin liberated (dissociated) from
these two proteins to be the origin of the peaks and
plateau, respectively (figs. 1—3), the results of the
HPLC analysis of the samples AS, ISi and IS2 can be
evaluated äs follows.
a) Sample AS is the serum of a healthy adult. The
peaks on the chromatogram of the diluted native
serum (fig. l, a) represent all light (over 436 nm)
absorbing serum components, i. e. bilirubin-stained ß-
lipoprotein and albumin, äs well äs oxyhaemoglobin,
transferrin, carotenoids, etc. The exogenous pigment,
added in gradually increasing amounts, was first (fig.
l, b — g) bound primarily by albumin due to its higher
binding capacity for bilirubin compared with that of
ß-lipoprotein. After albumin has bound a certäin
quantity of bilirubin, ß-lipoprotein becomes increas-
ingly involved in binding the exogenous pigment, since
in these heavily loaded serum samples its binding
capacity was comparable (cf. fig. l, h—j) or even
greater (cf. fig. l, k—m) than the "reserve" bilirubin
binding capacity of albumin. Simultaneously,· part of
the loosely bound (dissociable) pigment was adsorbed
by LiChrosorb Diol, yet continuously flushed off by
the protein(s)-containing eluent (cf. fig. l, g—m).
b) Sample ISj is the serum of a hyperbilirubinaemic
infant. The chromatograim of the diluted native serum
(fig. 2, a) reveals that the albumin loses part of the
bilirubin owing to the competitive affinity of the ad-
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sorbent for the pigment. This probably happens be-
cause the albumin is a less mature form compared
with that in sample AS. The load of further amounts
of exogenous pigment was also proportionally parti-
tioned between albumin and LiChrosorb Diol (cf. fig.
2, b —h). ß-Lipoprotein became stained only after a
relatively high pigment load (cf. fig. 2, i—m). The
very low bilirubin binding capacity of ß-lipoprotein
in this serum sample may also be due to the relatively
very low level of this protein in ISi.
c) Sample IS2 is the serum of another hyperbilirubi-
naemic infant. The chromatogram of the diluted na-
tive serum (fig. 3, a) reveals that both proteins partic-
ipated in the binding of endogenous bilirubin in this
sample. This may be accounted for by the relatively
low binding capacity of albumin (more immature
albumin than in sample ISj), and also by increased
bilirubin binding by possibly higher level of ß-lipo-
protein in the sample. Further increases in the amount
of exogenous pigment led to its extra and equal bind-
ing by the two bilirubin-binding proteins. Apart from
indirect speculative considerations, no conclusive ex-
planation can be provided for the clearly different
shape of the plateau on the IS2 chromatograms com-
pared with the plateau from serum ISi and AS (cf.
fig. 3 vs. figs. 2 (1)).
Clinical studies are necessary to assess the extent to
which the elution pattern from this HPLC assay (figs.
2 and 3) can reflect the risk of infant hyperbilirubi-
naemia turning into a pathological condition.
Conclusion
The HPLC assay described here provides a powerful
tool for the determination of "free" and protein-
bound bilirubin fractions in a sample of human serum.
The distribution of endo- and exogenous bilirubin
between albumin and ß-lipoprotein is clearly detect-
able even in a minute volume of serum.
Since both alteration of the albumin ability to bind
bilirubin and sudden changes in the level of serum
lipoproteins (3) occur frequently during the postnatal
period, the assay could be used to advantage partic-
ularly in paediatrics.
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